Information and usage recommendations for the C3 inhibitor Pegcetacoplan-Empaveli

Pegcetacoplan (Pegcetacoplan) is a new oral or subcutaneous injectionC3 inhibitor, suitable for adult patients with PNH and patients with C3G or IC-MPGN aged 12 years and above. Its mechanism of action blocks abnormal complement cascade reactions by inhibiting complement C3, thereby reducing hemoglobin hemolysis, reducing proteinuria and protecting vital organs. Overseas clinical practice shows that Pegtak can not only improve hemolysis-related symptoms, but also improve patients' quality of life. It is one of the important drugs in the field of complement inhibition treatment.

In terms of recommendations for use,PNH patients should undergo hematological evaluation and screening for infection risk, especially a history of encapsulated bacterial infection, before initiating treatment with PEGATOX. Patients 12 years and older with C3G or IC-MPGN are required to complete renal function and proteinuria assessment before treatment. During the treatment process, hemoglobin levels, hemolysis indicators and changes in renal function should be regularly monitored, while potential infections and adverse drug reactions should be observed. When first taking the medication or adjusting the dose, it is recommended to observe it in a medical institution to ensure patient safety.

Medication methods include subcutaneous injection and oral administration, and the dosage can be individually adjusted based on the patient's weight, severity of illness, and tolerance. Overseas guidelines point out that patients should receive adequate training before self-injection at home and understand drug storage conditions and injection techniques to ensure drug stability and efficacy. Regular follow-up and laboratory monitoring are important to ensure long-term efficacy and safety.

Overall, Pegtak has shown unique efficacy inPNH and C3-related kidney diseases. Through scientific individualized medication and strict monitoring, the patient's condition can be significantly improved. Doctors should consider the patient's age, weight, underlying diseases and infection risks when formulating treatment plans, and adjust dosage and frequency based on overseas clinical experience. Patients should strictly follow medical instructions during use, pay attention to changes in hematology and renal function indicators, and report any abnormal symptoms in a timely manner to ensure the safety and effectiveness of treatment.

Reference materials:https://empaveli.com/